GlassScriptPhysician profile
Heidi Henson
NPI 1760977573
$3,645.38
in general payments reported to CMS, 2019-2025
33 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $866 · 2022: $409 · 2023: $773 · 2024: $489 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $423.07 | 2021-2025 | |
| Medical Device Business Services, INC. | $329.99 | 2021 | |
| Amgen INC. | $317.57 | 2024-2025 | Evenity, Repatha, Otezla |
| Edwards Lifesciences Corporation | $297.72 | 2021-2023 | Sapien 3 Ultra Resilia |
| Spr Therapeutics, INC | $141.28 | 2023 | Sprint Pns System |
| Glaxosmithkline, LLC. | $137.95 | 2022 | |
| Medtronic, INC. | $125.42 | 2021 | |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Otsuka America Pharmaceutical, INC. | $113.23 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $98.22 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $85.96 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $84.07 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Corcept Therapeutics | $78.69 | 2025 | Korlym |
| Biotronik INC. | $73.75 | 2023 | Orsiro Mission |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.77 | 2025 | |
| Pfizer INC. | $56.14 | 2024-2025 | |
| Endogastric Solutions, INC | $51.89 | 2023 | Esophyx |
| Insulet Corporation | $36.84 | 2025 | Omnipod |
| Abiomed | $36.76 | 2024-2025 | Impella |
| Viatris Specialty LLC | $35.65 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $32.32 | 2022 | |
| Astellas Pharma US INC | $30.83 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $30.82 | 2024 | Keveyis |
| Biohaven Pharmaceuticals, INC. | $26.77 | 2021 | |
| Eisai INC. | $26.72 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.49 | 2022 | |
| Abbott Laboratories | $25.26 | 2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $21.05 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Mayne Pharma Commercial LLC | $20.49 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $20.30 | 2023 | Eliquis |
| Verona Pharma, INC. | $19.20 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $18.62 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.